Follow Us :

Your Trusted Source for Online Pharmaceutical Training and Blogs

Blog

By Dr Pramod Kumar Pandey - August 4, 2025

Dr Pramod Kumar Pandey BSc (Hons), MSc, PhD, founder of PharmaGuru.co, is a highly experienced Analytical Research Expert with over 31 years in the pharmaceutical industry. He has played a key role in advancing innovation across leading Indian and global pharmaceutical companies. He can be reached at admin@pharmaguru.co

Learn what extractables and leachables are, how they differ, and how they are tested in the pharmaceutical industry.

Extractables and Leachables Impurities in Pharmaceuticals: 5 Key Differences

Extractables and Leachables (E&L) are critical in ensuring the safety, efficacy, and quality of pharmaceuticals by identifying potential contaminants. Extractables are chemical compounds that can be released from packaging or process materials under aggressive conditions, while leachables are those that actually migrate into the drug product under normal storage or use conditions, potentially impacting its safety and quality.

These impurities can arise from packaging materials, manufacturing equipment, and drug delivery systems, posing potential risks to patient health. In this blog, I will discuss what extractables and leachables are, how they differ, and how they are tested in the pharmaceutical industry.

What Are Extractables and Leachables?

Extractables

Extractables are chemical compounds that can be drawn out (extracted) from packaging or device components when exposed to aggressive solvents under exaggerated conditions such as high temperature or extended time.

  • Example: Exposing a plastic syringe barrel to solvents like ethanol or hexane at elevated temperatures may release plasticizers or antioxidants.

Purpose of Testing: Extractables studies are typically conducted early in development to identify all potential compounds that could migrate into the drug product.

Leachables

Leachables are chemical compounds that actually migrate into the pharmaceutical product under normal storage, handling, and use conditions over time.

  • Example: If the same plastic syringe slowly releases a compound into a drug solution stored in it for months, that compound is a leachable.

Purpose of Testing: Leachables are evaluated in the final drug product to assess real-world patient exposure and toxicological risk.

You may like:

Key Differences: Extractables vs. Leachables

FeatureExtractablesLeachables
DefinitionCompounds that can be extracted under forced conditionsCompounds that do migrate into the product under normal use
When TestedEarly developmentLate-stage development and stability studies
ConditionsAggressive (e.g., high temp, solvents)Realistic (e.g., product formulation, storage)
PurposeRisk identificationRisk confirmation and control
Sample MatrixPackaging/device materialsFinal drug product

Why Are E&L Important?

E&L studies are critical for:

  • Ensuring patient safety (by minimising toxicological risks)
  • Meeting regulatory requirements (e.g., FDA, EMA, USP <1663> and <1664>)
  • Maintaining product integrity and shelf life
  • Demonstrating container-closure system compatibility

Testing and Evaluation of Extractables and Leachables

1. Extractables Studies

Conducted using aggressive extraction techniques:

  • Solvents: Water, ethanol, isopropanol, hexane, etc.
  • Conditions: Elevated temperature (40–70°C), extended time (up to 24–72 hrs)
  • Analytical Methods:
    • GC-MS (Gas Chromatography–Mass Spectrometry)
    • LC-MS (Liquid Chromatography–Mass Spectrometry)
    • ICP-MS (Inductively Coupled Plasma–Mass Spectrometry for metals)
    • FTIR, UV-Vis, and NMR as needed

2. Leachables Studies

Conducted under real-time or accelerated stability conditions using the actual drug product:

  • Sample Collection: At various time points (0, 3, 6, 12 months, etc.)
  • Analytical Methods: Similar to extractables, but with more sensitive detection
  • Toxicological Assessment: Identified leachables are evaluated for potential health risks using threshold of toxicological concern (TTC) or permitted daily exposure (PDE) limits.

Regulatory Landscape

Key guidelines and standards include:

  • FDA Guidance: Container Closure Systems for Packaging Human Drugs and Biologics
  • USP <1663> and <1664>: For extractables and leachables evaluation
  • ICH Q3D: Elemental impurities
  • EMA Guidelines: For plastic materials in contact with medicinal products

Conclusion

Extractables and leachables testing is not just a regulatory checkbox—it’s a patient safety imperative. By identifying and controlling E&L impurities, pharmaceutical manufacturers can ensure that packaging, devices, and storage systems do not compromise product safety, stability, or efficacy.

As drug delivery systems become more complex (e.g., inhalers, prefilled syringes, biologics), robust E&L testing strategies are more important than ever.

Related:

  1. Reporting Results of Pharmaceutical Impurities: A Case Study
  2. Control of Nitrosamine Impurities in Pharmaceuticals: Learn Easily in 7 Minutes
  3. How To Control Impurities In Pharmaceuticals: Get Mastery In 11 Minutes
  4. Specified and Unspecified Impurities In APIs: How To Define Limits
  5. ICPMS: A Key Tool For Elemental Impurities Analysis in Pharmaceuticals

FAQs

What is the difference between extractable and leachable?

Extractable substances are compounds that can be pulled out of a material under aggressive, often non-physiological conditions (e.g., using strong solvents, heat).
Leachable substances are compounds that actually migrate from a material under normal use conditions (e.g., during storage or contact with a drug product).

What are extractables and leachables drug substances?

Extractables in drug substances are chemical compounds that can be released from packaging, manufacturing components, or delivery systems when exposed to aggressive conditions.
Leachables are compounds that actually migrate into the drug product under normal storage or use conditions.

Further Reading

About Dr Pramod Kumar Pandey
Dr Pramod Kumar Pandey

Dr Pramod Kumar Pandey BSc (Hons), MSc, PhD, founder of PharmaGuru.co, is a highly experienced Analytical Research Expert with over 31 years in the pharmaceutical industry. He has played a key role in advancing innovation across leading Indian and global pharmaceutical companies. He can be reached at admin@pharmaguru.co

Join Our Newsletter

Leave a Reply

error: Content is protected !!
×